MetaCap

CytoMed Therapeutics Limited (GDTC)

NASDAQ: GDTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.755-0.018 (-2.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GDTC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.23
52-week range
0.68 – 2.12
Day range
0.7131 – 0.7848
Volume / Avg
15.48K / 15.69K
Beta
—

52-week range

$0.68$2.12

GDTC stock today

On Nov 20, GDTC ended the session at $0.755, shedding $0.018 (2.33%), versus the S&P 500's 3.70% decline. At this level, GDTC sits near the bottom of its 52-week range of $0.68 to $2.12: 64.4% below the high, set on Dec 8, 2025 and 11.0% above the low. GDTC is down 43.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 59.8%.

CytoMed Therapeutics has posted a net loss over the last twelve months (EPS of -$0.23), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CytoMed Therapeutics

Company profile

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury.

Industry
Biotechnology: Pharmaceutical Preparations
Headquarters
Singapore
Employees
42
IPO year
2023

Financial highlights

Full financials

In fiscal 2025, CytoMed Therapeutics generated $252,265 in revenue, up 395.9% from fiscal 2024. CytoMed Therapeutics reported a net loss of $3.1 million, compared with a loss of $1.8 million a year earlier. Diluted earnings per share came in at -$0.27.

CytoMed Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$252.26K$50.87K——
Growth+395.88%———
Net income$-3.10M$-1.84M$-3.13M$-2.34M
EPS (diluted)$-0.27$-0.16$-0.29$-0.30

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$4.16+450.99%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

GDTC news

All GDTC news

CytoMed Therapeutics peers

Health Care sector
GDTC peer companies
CompanyPrice% ChgMarket capCompare
BFRIBiofrontera Inc.0.53-7.02%$9.51Mvs GDTC
CMMBChemomab Therapeutics Ltd. ADR1.19+4.39%$9.58Mvs GDTC
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs GDTC
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs GDTC
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs GDTC
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs GDTC
HINDVyome Holdings Inc.1.20-17.24%$8.42Mvs GDTC
RADXRadiopharm Theranostics Limited ADR0.6304-9.71%$9.90Mvs GDTC

Indexes, lists and sector

CytoMed Therapeutics stock FAQ

What is CytoMed Therapeutics's stock price today?

GDTC last traded at $0.755 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.

What is the GDTC 52-week high?

The 52-week high for GDTC is $2.12 and the 52-week low is $0.68. The stock is currently 64.4% below its high.

Compare GDTC